Citations

Showing 10 of 108094 citations.

Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital ( SEARCH ) database
Herforth, Christine, Stroup, Sean P. , Chen, Zinan, Howard, Lauren E. , Freedland, Stephen J. , Amling, Christopher L. , Moreira, Daniel M. , Terris, Martha K. , Aronson, William J. , Cooperberg, Matthew R , Kane, Christopher J. , Howard, Lauren E , Stroup, Sean P

Mayo Clinic

BJU International | February 23, 2018 | Volume: 122 | Issue: 4 | Pages: 592-598

10.1111/bju.14178 | PMID 29473992 Get It

Objective To evaluate biochemical recurrence ( BCR ) patterns amongst men undergoing radical prostatectomy ( RP ) with specimens having negative ( NSM ), positive ( PSM ), and close surgical margins ( CSM ) from the Shared Equal Access Regional Cancer Hospital ( SEARCH ) cohort, as PSM after RP are a significant predictor of biochemical failure and possible disease progression, with CSM representing a diagnostic challenge for surgeons. Patients and Methods Men undergoing RP between 1988 and 2015 with known final pathological margin status were evaluated. The cohort was divided into three groups based on margin status; NSM , PSM , and CSM . CSM were defined by distance of tumour ≤1 mm from the surgical margin. BCR was defined as a prostate‐specific antigen ( PSA ) level of >0.2 ng/mL, two values at 0.2 ng/mL, or secondary treatment for an elevated PSA level. Predictors of BCR , metastases, and mortality were analysed using Cox proportional hazard models. Results Of 5515 men in the SEARCH database, 4337 (79%) men met criteria for inclusion in the analysis. Of these, 2063 (48%) had NSM , 1902 (44%) had PSM , and 372 (8%) had CSM . On multivariable analysis, relative to NSM , men with CSM had a higher risk of BCR (hazard ratio [ HR ] 1.51, 95% confidence interval [ CI ] 1.25–1.82; P < 0.001) but a decreased risk of BCR when compared to those men with PSM ( HR 2.09, 95% CI 1.86–2.36; P < 0.001). Metastases, prostate cancer‐specific mortality and all‐cause mortality did not differ based on margin status alone. Conclusions Management of men with CSM is a diagnostic challenge, with a disease course that is not entirely benign. The evaluation of other known risk factors probably provides greater prognostic value for these men and may ultimately better select those who may benefit from adjuvant therapy.
Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP ‐9 and MMP ‐14
Shirian, Jason , Arkadash, Valeria, Cohen, Itay , Sapir, Tamila, Radisky, Evette S. , Papo, Niv , Shifman, Julia M. , Radisky, Evette S

Mayo Clinic

FEBS Letters | February 23, 2018 | Volume: 592 | Issue: 7 | Pages: 1122-1134

10.1002/1873-3468.13016 | PMID 29473954 Get It

MMP ‐14 and MMP ‐9 are two well‐established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inhibitor starting from a nonspecific MMP inhibitor, N‐ TIMP 2. The engineered purified N‐ TIMP 2 variants showed enhanced specificity toward MMP ‐14 and MMP ‐9 relative to a panel of off‐target MMP s. MMP ‐specific N‐ TIMP 2 sequence signatures were obtained that could be understood from the structural perspective of MMP /N‐ TIMP 2 interactions. Our MMP ‐9 inhibitor exhibited 1000‐fold preference for MMP ‐9 vs. MMP ‐14, which is likely to translate into significant differences under physiological conditions. Our results provide new insights regarding evolution of promiscuous proteins and optimization strategies for design of inhibitors with single‐target specificities.
Serum insulin‐like growth factor (IGF)‐I and IGF binding protein‐3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank
Oh, Hannah , Horne, Hisani N., Xiang, Jackie , Pollak, Michaël , Brinton, Louise A. , Storniolo, Anna Maria , Sherman, Mark E. , Figueroa, Jonine D. , Pollak, Michael N , Figueroa, Jonine D , Pfeiffer, Ruth M. , Falk, Roni T. , Gierach, Gretchen L.

Mayo Clinic

International Journal of Cancer | February 23, 2018 | Volume: 143 | Issue: 3 | Pages: 496-507

10.1002/ijc.31333 | PMID 29473153 Get It

Lesser degrees of terminal duct lobular unit (TDLU) involution, as reflected by higher numbers of TDLUs and acini/TDLU, are associated with elevated breast cancer risk. In rodent models, the insulin‐like growth factor (IGF) system regulates involution of the mammary gland. We examined associations of circulating IGF measures with TDLU involution in normal breast tissues among women without precancerous lesions. Among 715 Caucasian and 283 African American (AA) women who donated normal breast tissue samples to the Komen Tissue Bank between 2009 and 2012 (75% premenopausal), serum concentrations of IGF‐I and binding protein (IGFBP)‐3 were quantified using enzyme‐linked immunosorbent assay. Hematoxilyn and eosin‐stained tissue sections were assessed for numbers of TDLUs (“TDLU count”). Zero‐inflated Poisson regression models with a robust variance estimator were used to estimate relative risks (RRs) for association of IGF measures (tertiles) with TDLU count by race and menopausal status, adjusting for potential confounders. AA (vs. Caucasian) women had higher age‐adjusted mean levels of serum IGF‐I (137 vs. 131 ng/mL, p = 0.07) and lower levels of IGFBP‐3 (4165 vs. 4684 ng/mL, p < 0.0001). Postmenopausal IGFBP‐3 was inversely associated with TDLU count among AA (RRT3vs.T1 = 0.49, 95% CI = 0.28–0.84, p‐trend = 0.04) and Caucasian (RRT3vs.T1=0.64, 95% CI = 0.42–0.98, p‐trend = 0.04) women. In premenopausal women, higher IGF‐I:IGFBP‐3 ratios were associated with higher TDLU count in Caucasian (RRT3vs.T1=1.33, 95% CI = 1.02–1.75, p‐trend = 0.04), but not in AA (RRT3vs.T1=0.65, 95% CI = 0.42–1.00, p‐trend = 0.05), women. Our data suggest a role of the IGF system, particularly IGFBP‐3, in TDLU involution of the normal breast, a breast cancer risk factor, among Caucasian and AA women.
Use of volumetric laser endomicroscopy for determining candidates for endoscopic therapy in superficial esophageal squamous cell carcinoma
Trindade, Arvind J. , Benias, Petros C. , Inamdar, Sumant , Fan, Cathy, Sethi, Amrita , Fukami, Norio , Andalib, Iman , Sejpal, Divyesh V., Rishi, Arvind , Kahn, Allon , Trindade, Arvind J , Fukami, Norio , Kahaleh, Michel

Mayo Clinic

United European Gastroenterology Journal | February 23, 2018 | Volume: 6 | Issue: 6 | Pages: 838-845

10.1177/2050640618761701 | PMID 30023061 Get It

BackgroundAccurate staging of superficial esophageal squamous cell cancer (ESCC) for endoscopic therapy is challenging. Optical coherence tomography (OCT) has been shown to be superior to high‐resolution endoscopic ultrasound (EUS). Volumetric Laser Endomicroscopy (VLE), a second‐generation OCT, has recently become commercially available.ObjectiveTo assess if VLE can determine which patients with superficial ESSC can undergo endoscopic therapy.MethodsThis is a multi‐center retrospective study. Patients were included if (a) they had visible ESCC, (b) they underwent VLE and EUS for staging, and c) if superficial disease was suspected then endoscopic resection had to be performed to have accurate histology to compare the VLE scan to. VLE scans were then compared to the gold standard: histology for superficial disease and EUS for disease T1b and greater.ResultsSeventeen patients were included with the following disease: squamous intraepithelial neoplasia (4 patients), T1a disease (6 patients), T1b (2 patients), T2 disease (2 patients) and T3 disease (3 patients). VLE was able to distinguish superficial disease, defined as disease limited up to the lamina propria, from non‐superficial disease in all cases.ConclusionsVLE may be able to determine which ESCC patients are candidates for endoscopic therapy. Prospective studies are needed to confirm this.
Clinical Evolution in Patients With New‐Onset Inflammatory Back Pain
Wang, Runsheng , Crowson, Cynthia S. , Wright, Kerry , Ward, Michael M.

Mayo Clinic

Arthritis & Rheumatology | February 23, 2018 | Volume: 70 | Issue: 7 | Pages: 1049-1055

10.1002/art.40460 | PMID 29471593 Get It

ObjectiveInflammatory back pain (IBP) is often an early manifestation of spondyloarthritis (SpA), but the prognosis of patients with incident IBP is unknown. This study was undertaken to investigate long‐term outcomes in patients with IBP, and predictors of progression to SpA, in a population‐based cohort.MethodsWe conducted a retrospective, longitudinal study using the Rochester Epidemiology Project, a longstanding population‐based cohort of residents of Olmsted County, MN. Patients ages 16–35 years with clinical visits for back pain from 1999 to 2003 were identified, and we screened these patients for the presence of new‐onset IBP and performed medical record reviews to collect data on clinical, laboratory, and imaging features of SpA. Outcomes in these patients were followed up until July 2016. We used survival analysis for competing risks to examine progression to either SpA, a non‐SpA diagnosis, or resolution of back pain. Recursive partitioning was used to identify predictors of progression to SpA.ResultsAmong 5,304 patients with back pain, we identified 124 patients with new‐onset IBP. After a median follow‐up of 13.2 years, IBP had progressed to SpA in 39 patients, 15 patients developed a non‐SpA diagnosis, and 58 patients had resolution of IBP. At 10 years, the probability of having SpA was 30%, while the probability of resolution of IBP was 43%. The most important predictors for progression to SpA were uveitis, male sex, and family history of SpA.ConclusionIn a minority of patients, new‐onset IBP progresses to SpA, while IBP resolves in many. That IBP often resolves may explain the difference between the prevalence of IBP (3–6%) and the prevalence of SpA (0.4–1.3%).
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Dodick, David W. , Ashina, Messoud , Brandes, Jan Lewis, Kudrow, David, Lantéri‐Minet, Michel , Osipova, V. В. , Palmer, Kerry, Picard, Hernàn , Mikol, Daniel D., Lenz, Robert , Dodick, David W , Ashina, Messoud

Mayo Clinic

Cephalalgia | February 23, 2018 | Volume: 38 | Issue: 6 | Pages: 1026-1037

10.1177/0333102418759786 | PMID 29471679 Get It

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. Methods In this randomized, double-blind, placebo-controlled, phase 3 study, 577 adults with episodic migraine were randomized to placebo or 70 mg erenumab; 570 patients were included in efficacy analyses. Primary endpoint was change in monthly migraine days. Secondary endpoints were ≥50% reduction in monthly migraine days, change in acute migraine-specific medication treatment days, and ≥5-point reduction in Physical Impairment and Impact on Everyday Activities domain scores measured by the Migraine Physical Function Impact Diary. All endpoints assessed change from baseline at month 3. Results Patients receiving erenumab experienced −2.9 days change in monthly migraine days, compared with −1.8 days for placebo, least-squares mean (95% CI) treatment difference of −1.0 (−1.6, −0.5) ( p < 0.001). A ≥ 50% reduction in monthly migraine days was achieved by 39.7% (erenumab) and 29.5% (placebo) of patients (OR:1.59 (95% CI: 1.12, 2.27) ( p = 0.010). Migraine-specific medication treatment days were reduced by −1.2 (erenumab) and −0.6 (placebo) days, a treatment difference of −0.6 (−1.0, −0.2) ( p = 0.002). The ≥5-point reduction rates in Migraine Physical Function Impact Diary – Physical Impairment were 33.0% and 27.1% (OR:1.33 (0.92, 1.90) ( p = 0.13) and in Migraine Physical Function Impact Diary – Everyday Activities were 40.4% and 35.8% (OR:1.22 (0.87, 1.71) ( p = 0.26). Safety and adverse event profiles of erenumab were similar to placebo. Most frequent adverse events were upper respiratory tract infection, injection site pain, and nasopharyngitis. Conclusions As a preventive treatment of episodic migraine, erenumab at a dosage of 70 mg monthly significantly reduced migraine frequency and acute migraine-specific medication use. (Funded by Amgen). Trial registration ClinicalTrials.gov, NCT02483585.
Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma
Marinelli, John P. , Link, Michael J., Moore, Eric J. , Abel, Kathryn M. Van , Peck, Brandon W., Lohse, Christine M. , Janus, Jeffrey R. , Van Abel, Kathryn M , Gompel, Jamie J. Van , Price, Daniel L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 23, 2018 | Volume: 79 | Issue: 05 | Pages: 495-500

10.1055/s-0038-1625977 | PMID 30210978 Get It

Objectives Neck metastases in patients with esthesioneuroblastoma (ENB) constitute the most significant predictor of poor long-term survival. Recently, researchers discovered the existence of dural lymphatic channels that drain to the cervical lymph nodes. From this physiologic basis, we hypothesized that patients with ENB who develop dural invasion (DI) would exhibit a proclivity for neck metastases. Design Retrospective review. Setting Tertiary referral center. Participants All patients treated for ENB from January 1, 1994 to December 31, 2015. Main Outcome Measures Incidence, laterality, and recurrence rate of neck metastases by DI status. Results Sixty-one patients were identified (38% female; median age 49, range, 10–80), 34 (56%) of whom had DI and 27 (44%) did not. Of patients with DI, 50% presented with or developed neck disease following treatment compared with just 22% of those without DI (p = 0.026). Bilateral neck disease was more common in patients with DI (11/34, 32%) compared with those without (2/27, 7%) (p = 0.018). Five-year regional recurrence-free survival rates were 88% for those without and 64% for those with DI (p = 0.022). Kadish C patients with DI were more likely to develop regional recurrence when compared with Kadish C without DI and Kadish A/B (p = 0.083). Further, Kadish C patients with DI displayed worse overall survival than Kadish C without DI and Kadish A/B. Kadish D patients displayed the worst overall survival. The difference in overall survival among these four groups was significant (p < 0.001). Conclusion DI by ENB is associated with increased incidence of cervical nodal metastases, bilateral neck disease, worse regional recurrence-free survival, and poorer overall survival. These data support the division of Kadish C by DI status.
Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer
Hlady, Ryan A. , Robertson, Keith D. , Robertson, Keith D

Mayo Clinic

Seminars in Liver Disease | February 22, 2018 | Volume: 38 | Issue: 01 | Pages: 041-050

10.1055/s-0037-1621712 | PMID 29471564 Get It

AbstractHepatocellular carcinoma (HCC) is the most prevalent primary tumor of the liver, and is steadily becoming one of the most lethal cancers worldwide. Liver resection, which is the recommended procedure for early localized HCC, results in frequent recurrence (50–70%), while the standard of care for late-stage HCC, multikinase inhibitors, only improves survival by a few months. The lack of success for these treatment modalities is attributable, at least in part, to marked phenotypic heterogeneity within the tumor. Intratumoral heterogeneity (ITH) has emerged as a defining characteristic of human tumors, with individual cancer cells displaying distinct differences in properties including growth rate, metastatic capacity, and response to treatment. This heterogeneity, which is unlikely to be captured from a biopsy, impacts outcome because a single treatment targeting one cancer-specific pathway would spare tumor cells having distinct characteristics. Development of effective biomarkers remains a major challenge for similar reasons. Understanding, interpreting, and circumventing the impact of ITH is therefore paramount for developing reliable biomarkers and designing effective individualized treatment strategies for HCC.
Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial
Chen, John J. , Majed, Masoud , Jitprapaikulsan, Jiraporn , Fryer, James P., Leavitt, Jacqueline A., McKeon, Andrew , Pittock, Sean J. , Pittock, S J , McKeon, Andrew , Chen, John J , Tobin, W. Oliver , Flanagan, Eoin P.

Mayo Clinic

JAMA Ophthalmology | February 22, 2018 | Volume: 136 | Issue: 4 | Pages: 419

10.1001/jamaophthalmol.2017.6757 | PMID 29470571 Get It

Factors Associated With Health-Related Quality of Life in Medically and Surgically Treated Patients With Glaucoma
Khanna, Cheryl L. , Leske, David A. , Holmes, Jonathan M. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | February 22, 2018 | Volume: 136 | Issue: 4 | Pages: 348

10.1001/jamaophthalmol.2018.0012 | PMID 29470573 Get It